BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D

PARP2 inhibitor

Associations(4)